Cytek Biosciences to Report First Quarter Financial Results on May 11, 2022

Rhea-AI Summary

Cytek Biosciences (Nasdaq: CTKB) will report its Q1 2022 financial results after market close on May 11, 2022. Following the earnings announcement, management will host a webcast conference call at 2:00 p.m. PT / 5:00 p.m. ET to discuss the results, business developments, and future outlook. Cytek is known for its Full Spectrum Profiling™ technology, providing advanced cell analysis solutions.

Positive

• Scheduled conference call for Q1 results may enhance investor engagement.

Negative

• None.

FREMONT, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced it will report financial results for the first quarter 2022 after market close on Wednesday, May 11^th, 2022. The company’s management will webcast a corresponding conference call beginning at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss its results, business developments and outlook.

Live audio of the webcast will be available on the “Investors” section of the company website at investors.cytekbio.com

About Cytek Biosciences
Cytek Biosciences is a leading cell analysis solutions company advancing the next generation of cell analysis tools by delivering high-resolution, high-content and high-sensitivity cell analysis utilizing its patented Full Spectrum Profiling™ (FSP™) technology. Cytek’s novel approach harnesses the power of information within the entire spectrum of a fluorescent signal to achieve a higher level of multiplexing with exquisite sensitivity. Cytek’s FSP platform includes its core instruments, the Aurora and Northern Lights™ systems, its cell sorter, the Aurora CS, and reagents, software and services to provide a comprehensive and integrated suite of solutions for its customers. Cytek is headquartered in Fremont, California with offices and distribution channels across the globe.

Other than Cytek’s Northern Lights CLC system, which is available for clinical use in China and the European Union, Cytek’s products are for research use only – not for use in diagnostic procedures or for clinical purposes.

Cytek, Full Spectrum Profiling, FSP and Northern Lights are trademarks or registered trademarks of Cytek Biosciences, Inc.

Investor Relations Contact:
Paul D. Goodson
Head of Investor Relations
pgoodson@cytekbio.com 

Media Contact:
Stephanie Olsen
Lages & Associates
(949) 453-8080
stephanie@lages.com 

FAQ

When will Cytek Biosciences report its Q1 2022 financial results?

Cytek Biosciences will report its Q1 2022 financial results after market close on May 11, 2022.

What time is the conference call for Cytek's Q1 results?

The conference call for Cytek's Q1 results will begin at 2:00 p.m. PT / 5:00 p.m. ET on May 11, 2022.

Where can I listen to Cytek's Q1 conference call?

You can listen to Cytek's Q1 conference call on the 'Investors' section of their website at investors.cytekbio.com.

What technology does Cytek Biosciences specialize in?

Cytek Biosciences specializes in Full Spectrum Profiling™ for advanced cell analysis solutions.